|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ayoub WS, Steggerda J, Yang JD, Kuo A,
Sundaram V and Lu SC: Current status of hepatocellular carcinoma
detection: Screening strategies and novel biomarkers. Ther Adv Med
Oncol. 11:17588359198691202019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alqahtani A, Khan Z, Alloghbi A, Said
Ahmed TS, Ashraf M and Hammouda DM: Hepatocellular carcinoma:
Molecular mechanisms and targeted therapies. Medicina (Kaunas).
55:E5262019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Golabi P, Fazel S, Otgonsuren M, Sayiner
M, Locklear CT and Younossi ZM: Mortality assessment of patients
with hepatocellular carcinoma according to underlying disease and
treatment modalities. Medicine (Baltimore). 96:e59042017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dhanasekaran R, Venkatesh SK, Torbenson MS
and Roberts LR: Clinical implications of basic research in
hepatocellular carcinoma. J Hepatol. 64:736–745. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng H, Sun G, Chen H and Li Y, Han Z and
Li Y, Zhang P, Yang L and Li Y: Trends in the treatment of advanced
hepatocellular carcinoma: Immune checkpoint blockade immunotherapy
and related combination therapies. Am J Cancer Res. 9:1536–1545.
2019.PubMed/NCBI
|
|
8
|
Kumari R, Sahu MK, Tripathy A, Uthansingh
K and Behera M: Hepatocellular carcinoma treatment: Hurdles,
advances and prospects. Hepat Oncol. 5:HEP082018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Neureiter D, Stintzing S, Kiesslich T and
Ocker M: Hepatocellular carcinoma: Therapeutic advances in
signaling, epigenetic and immune targets. World J Gastroenterol.
25:3136–3150. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sana J, Faltejskova P, Svoboda M and Slaby
O: Novel classes of non-coding RNAs and cancer. J Transl Med.
10:1032012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
ENCODE Project Consortium, . An integrated
encyclopedia of DNA elements in the human genome. Nature.
489:57–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kopp F and Mendell JT: Functional
classification and experimental dissection of long noncoding RNAs.
Cell. 172:393–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang B and Zhang R: Regulatory non-coding
RNAs: Revolutionizing the RNA world. Mol Biol Rep. 41:3915–3923.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Smekalova EM, Kotelevtsev YV, Leboeuf D,
Shcherbinina EY, Fefilova AS, Zatsepin TS and Koteliansky V: lncRNA
in the liver: Prospects for fundamental research and therapy by RNA
interference. Biochimie. 131:159–172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartonicek N, Maag JL and Dinger ME: Long
noncoding RNAs in cancer: Mechanisms of action and technological
advancements. Mol Cancer. 15:432016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niu ZS, Niu XJ and Wang WH: Long
non-coding RNAs in hepatocellular carcinoma: Potential roles and
clinical implications. World J Gastroenterol. 23:5860–5874. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Klingenberg M, Matsuda A, Diederichs S and
Patel T: Non-coding RNA in hepatocellular carcinoma: Mechanisms,
biomarkers and therapeutic targets. J Hepatol. 67:603–618. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shibata C, Otsuka M, Kishikawa T, Ohno M,
Yoshikawa T, Takata A and Koike K: Diagnostic and therapeutic
application of noncoding RNAs for hepatocellular carcinoma. World J
Hepatol. 7:1–6. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun J, Bie B, Zhang S, Yang J and Li Z:
Long non-coding RNAs: Critical players in hepatocellular carcinoma.
Int J Mol Sci. 15:20434–20448. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi L, Peng F, Tao Y, Fan X and Li N:
Roles of long noncoding RNAs in hepatocellular carcinoma. Virus
Res. 223:131–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Amin MB: American Joint Committee on
Cancer Staging Manual. 8th. Springer; New York, NY: pp. 103–111.
2017, PubMed/NCBI
|
|
23
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan SX, Wang J, Yang F, Tao QF, Zhang J,
Wang LL, Yang Y, Liu H, Wang ZG, Xu QG, et al: Long noncoding RNA
DANCR increases stemness features of hepatocellular carcinoma by
derepression of CTNNB1. Hepatology. 63:499–511. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu P, Wang Y, Huang G, Ye B, Liu B, Wu J,
Du Y, He L and Fan Z: lnc-β-Catm elicits EZH2-dependent β-catenin
stabilization and sustains liver CSC self-renewal. Nat Struct Mol
Biol. 23:631–639. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ,
Tao QF, Liu F, Pan W, Wang TT, Zhou CC, et al: A long noncoding RNA
activated by TGF-β promotes the invasion-metastasis cascade in
hepatocellular carcinoma. Cancer Cell. 25:666–681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zheng Q, Lin Z, Li X, Xin X, Wu M, An J,
Gui X, Li T, Pu H, Li H and Lu D: Inflammatory cytokine IL6
cooperates with CUDR to aggravate hepatocyte-like stem cells
malignant transformation through NF-kB signaling. Sci Rep.
6:368432016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Sun W, Shen W, Xia M, Chen C,
Xiang D, Ning B, Cui X, Li H, Li X, et al: Long non-coding RNA DILC
regulates liver cancer stem cells via IL-6/STAT3 axis. J Hepatol.
64:1283–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lv L, Chen G, Zhou J, Li J and Gong J:
WT1-AS promotes cell apoptosis in hepatocellular carcinoma through
down-regulating of WT1. J Exp Clin Cancer Res. 34:1192015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang F, Yuan JH, Wang SB, Yang F, Yuan SX,
Ye C, Yang N, Zhou WP, Li WL, Li W and Sun SH: Oncofetal long
noncoding RNA PVT1 promotes proliferation and stem cell-like
property of hepatocellular carcinoma cells by stabilizing NOP2.
Hepatology. 60:1278–1290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guo W and Liu S, Cheng Y, Lu L, Shi J, Xu
G, Li N, Cheng K, Wu M, Cheng S and Liu S: ICAM-1-related noncoding
RNA in cancer stem cells maintains ICAM-1 expression in
hepatocellular carcinoma. Clin Cancer Res. 22:2041–2050. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP,
Wang F and Sun SH: Repression of the long noncoding RNA-LET by
histone deacetylase 3 contributes to hypoxia-mediated metastasis.
Mol Cell. 49:1083–1096. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang TH, Yu CC, Lin YS, Chen TC, Yeh CT,
Liang KH, Shieh TM, Chen CY and Hsueh C: Long noncoding RNA
CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by
regulating HIF-1α activity and inhibiting epithelial-mesenchymal
transition. Oncotarget. 7:43588–43603. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Panzitt K, Tschernatsch MM, Guelly C,
Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder
R, Trauner M and Zatloukal K: Characterization of HULC, a novel
gene with striking up-regulation in hepatocellular carcinoma, as
noncoding RNA. Gastroenterology. 132:330–342. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bao H and Su H: Long Noncoding RNAs Act as
novel biomarkers for hepatocellular carcinoma: Progress and
prospects. Biomed Res Int. 2017:60494802017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng C, Hao H, Chen L and Shao J: Long
noncoding RNAs as novel serum biomarkers for the diagnosis of
hepatocellular carcinoma: A systematic review and meta-analysis.
Clin Transl Oncol. 19:961–968. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
George J and Patel T: Noncoding RNA as
therapeutic targets for hepatocellular carcinoma. Semin Liver Dis.
35:63–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ma L, Chua MS, Andrisani O and So S:
Epigenetics in hepatocellular carcinoma: An update and future
therapy perspectives. World J Gastroenterol. 20:333–345. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Parasramka MA, Maji S, Matsuda A, Yan IK
and Patel T: Long non-coding RNAs as novel targets for therapy in
hepatocellular carcinoma. Pharmacol Ther. 161:67–78. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Meijer D, van Agthoven T, Bosma PT, Nooter
K and Dorssers LC: Functional screen for genes responsible for
tamoxifen resistance in human breast cancer cells. Mol Cancer Res.
4:379–386. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van Agthoven T, Godinho MF, Wulfkuhle JD,
Petricoin EF 3rd and Dorssers LC: Protein pathway activation
mapping reveals molecular networks associated with antiestrogen
resistance in breast cancer cell lines. Int J Cancer.
131:1998–2007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Godinho MF, Wulfkuhle JD, Look MP,
Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC
and van Agthoven T: BCAR4 induces antioestrogen resistance but
sensitises breast cancer to lapatinib. Br J Cancer. 107:947–955.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Godinho M, Meijer D, Setyono-Han B,
Dorssers LC and van Agthoven T: Characterization of BCAR4, a novel
oncogene causing endocrine resistance in human breast cancer cells.
J Cell Physiol. 226:1741–1749. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Godinho MF, Sieuwerts AM, Look MP, Meijer
D, Foekens JA, Dorssers LC and van Agthoven T: Relevance of BCAR4
in tamoxifen resistance and tumour aggressiveness of human breast
cancer. Br J Cancer. 103:1284–1291. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ju L, Zhou YM and Yang GS: Up-regulation
of long non-coding RNA BCAR4 predicts a poor prognosis in patients
with osteosarcoma, and promotes cell invasion and metastasis. Eur
Rev Med Pharmacol Sci. 20:4445–4451. 2016.PubMed/NCBI
|
|
46
|
Li Q, Dai Y, Wang F and Hou S:
Differentially expressed long non-coding RNAs and the prognostic
potential in colorectal cancer. Neoplasma. 63:977–983. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li N, Gao WJ and Liu NS: LncRNA BCAR4
promotes proliferation, invasion and metastasis of non-small cell
lung cancer cells by affecting epithelial-mesenchymal transition.
Eur Rev Med Pharmacol Sci. 21:2075–2086. 2017.PubMed/NCBI
|
|
48
|
Shui X, Zhou C, Lin W, Yu Y, Feng Y and
Kong J: Long non-coding RNA BCAR4 promotes chondrosarcoma cell
proliferation and migration through activation of mTOR signaling
pathway. Exp Biol Med (Maywood). 242:1044–1050. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang L, Chunyan Q, Zhou Y, He Q, Ma Y, Ga
Y and Wang X: BCAR4 increase cisplatin resistance and predicted
poor survival in gastric cancer patients. Eur Rev Med Pharmacol
Sci. 21:4064–4070. 2017.PubMed/NCBI
|
|
50
|
Yang H, Yan L, Sun K, Sun X, Zhang X, Cai
K and Song T: LncRNA BCAR4 increases viability, invasion and
migration non-small cell lung cancer cells by targeting
glioma-associated oncogene 2(GLI2). Oncol Res. 27:359–369. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ouyang S, Zheng X, Zhou X, Chen Z, Yang X
and Xie M: LncRNA BCAR4 promotes colon cancer progression via
activating Wnt/betaβ-catenin signaling. Oncotarget. 8:92815–92826.
2017. View Article : Google Scholar : PubMed/NCBI
|
